

The *Candida albicans* Cdk8-dependent phosphoproteome reveals repression of hyphal growth through a Flo8-dependent pathway

Jeffrey M. Hollomon^{#a}, Zhongle Liu^{# a}, Scott F. Rusin^b, Nicole P. Jenkins^b,
Allia K. Smith^a, Katja Koeppen^a, Arminja N. Kettenbach^b, Lawrence C. Myers^{b*},
and Deborah A. Hogan^{a*}

^aDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755

^bDepartment of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755

[#]Both authors contributed equally to this work.

*To whom correspondence should be addressed:

Deborah A. Hogan

Geisel School of Medicine at Dartmouth

Rm 208 Vail Building, Hanover, NH 03755

E-mail: dhogan@dartmouth.edu

Tel: (603) 650-1252

Lawrence Myers

Geisel School of Medicine at Dartmouth

Vail Building, Hanover, NH 03755

E-mail: lawrence.c.myers@dartmouth.edu

1 **Abstract:**

2 Ssn3, also known as Cdk8, is a member of the four protein Cdk8 submodule
3 within the multi-subunit Mediator complex involved in the co-regulation of transcription.
4 In *Candida albicans*, the loss of Ssn3 kinase activity affects multiple phenotypes
5 including cellular morphology, metabolism, nutrient acquisition, immune cell
6 interactions, and drug resistance. In these studies, we generated a strain in which Ssn3
7 was replaced with a functional variant of Ssn3 that can be rapidly and selectively
8 inhibited by the ATP analog 3-MB-PP1. Consistent with *ssn3* null mutant and kinase
9 dead phenotypes, inhibition of Ssn3 kinase activity promoted hypha formation.
10 Furthermore, the increased expression of hypha-specific genes was the strongest
11 transcriptional signal upon inhibition of Ssn3 in transcriptomics analyses. Rapid
12 inactivation of Ssn3 was used for phosphoproteomic studies performed to identify Ssn3
13 kinase substrates associated with filamentation potential. Both previously validated
14 and novel Ssn3 targets were identified. Protein phosphorylation sites that were reduced
15 specifically upon Ssn3 inhibition included two sites in Flo8 which is a transcription factor
16 known to positively regulate *C. albicans* morphology. Mutation of the two Flo8
17 phosphosites (threonine 589 and serine 620) was sufficient to increase Flo8-HA levels
18 and Flo8 dependent activity, suggesting that Ssn3 kinase activity negatively regulates
19 Flo8. Previous work has also shown that loss of Ssn3 activity leads to increased
20 alkalization of medium with amino acids. Here, we show that *FLO8* and *STP2*, a
21 transcription factor involved in amino acid utilization, are required for *ssn3Δ/Δ*
22 phenotype, but that loss of the Ssn3 phosphosites identified in Flo8 was not sufficient
23 to phenocopy the *ssn3Δ/Δ* mutant. These data highlight the spectrum of processes

24 affected by the modulation of Ssn3 activity and underscore the importance of
25 considering Ssn3 function in the control of transcription factor activities.

26

27 **Introduction**

28 One of the important roles of the Mediator transcriptional co-regulatory complex is
29 to link the activity of promoter-bound transcriptional factors to the basal transcription
30 machinery. The Cdk8 sub-module of Mediator plays important roles in modulating the
31 activity of Mediator itself as well as the activity of transcription factors, among other
32 proteins. In *Candida albicans*, like in other eukaryotes, the Cdk8 module consists of four
33 subunits: the catalytic subunit Ssn3 (Cdk8), Ssn8 (CycC), Med12 (Srb8), and Med13
34 (Srb9). Ssn3, the catalytic component of the Cdk8 module, is a cyclin-dependent like
35 kinase and its activity depends on the cyclin-like protein Ssn8. Across eukaryotic species,
36 the Cdk8 kinase has been shown to be particularly important for regulation during
37 metabolism and morphology (1, 2). In mammals, for example, glycolysis, lipogenesis
38 and immune responses are influenced by Cdk8 phosphorylation of specific regulators (3-
39 5). In *S. cerevisiae*, Ssn3(Cdk8) has been well-studied for its roles in metabolism (6, 7)
40 and its negative regulation of pseudohyphal growth through Ste12 (8) and Phd1 (9, 10).
41 The Cdk8 module is of particular interest for its role in transitions between growth
42 conditions and during development as cells need to rapidly make coordinated changes to
43 the abundances and activities of cellular regulators.

44 In *C. albicans*, null mutations in either *SSN3* or *SSN8* result in interrelated,
45 pleiotropic phenotypes. *SSN3* null mutants had increased induction of drug resistance
46 elements (11) and increased resistance to the effects of bacterially-produced metabolic
47 inhibitors (12). The *ssn3Δ/Δ* leads to a hyperwrinkled colony morphology, increased
48 respiratory metabolism and amino acid utilization (12), and fraction of Ras1 in its active
49 GTP-bound state (13). Mutation of *SSN3* was found to unmask an alternative

50 filamentation pathway in macrophages (14). Recent work by Lu and colleagues (15) found
51 that changes in Ssn3 activity in response to CO₂, mediated by the Ptc2 phosphatase, led
52 to decreased Ssn3 phosphorylation and decreased inhibition of Ume6, a positive
53 regulator of hyphal growth.

54 Here, we utilize analog-sensitive variants of *C. albicans* Ssn3, as has been
55 performed in *S. cerevisiae* and in human cells, (3, 16), to study the immediate effects of
56 inhibition of Cdk8 kinase activity on *C. albicans*. Under conditions that do not promote
57 hyphal growth in wild-type strains, Ssn3 inhibition led to the formation of hyphae. We used
58 these conditions to elucidate the *C. albicans* Cdk8 regulon as it related to the control of
59 morphology using phosphoproteomic and transcriptomic analysis of cells shortly after
60 Ssn3 inhibition. Flo8, a transcription factor that positively regulates hyphal growth (17,
61 18), was identified in the phosphoproteomics analysis as a candidate for Ssn3 regulation,
62 and transcriptomics data showed alterations in hypha-specific genes known to be
63 regulated by Flo8. Deletion of Ssn3-phosphosites in Flo8 was sufficient to affect protein
64 levels and morphology. Additional assays suggest that Flo8 plays major roles in Ssn3-
65 regulated control of metabolism. The data in this manuscript indicate the spectrum of
66 proteins that are altered, directly or indirectly, by Ssn3 kinase activity as cells respond to
67 changing environments. While these studies focus on Flo8, our data show that other
68 transcription factors, including Efg1 and Eed1 are also likely Ssn3 targets and thus the
69 tools and insights presented here may aid in the study of diverse proteins involved in
70 morphology, virulence and drug resistance.

71 **RESULTS:**

72 **3-MB-PP1 inhibits analog-sensitive Ssn3**

73 To investigate the direct targets of the *C. albicans* Ssn3 kinase, we sought to
74 develop a strain in which Ssn3 kinase activity could be rapidly inhibited using approaches
75 that have been successfully applied in *S. cerevisiae* (16). Based on the alignment of the
76 *C. albicans* and *S. cerevisiae* Ssn3 orthologs, we predicted a phenylalanine to glycine
77 substitution at position 257 would yield a variant that retained the functions of the wild-
78 type kinase, while still being able to be specifically inhibited by the ATP analog 3-MB-PP1
79 (19). The Ssn3^{F257G} was constructed and is henceforth referred to as the analog-sensitive
80 variant, Ssn3^{AS}.

81 We first assessed the inhibition of Ssn3^{AS} by 3-MB-PP1 with an *in vitro* kinase
82 assay using purified Mediator complex containing the Cdk8 module. Ssn3^{WT} or Ssn3^{AS}
83 were expressed in a background that contained a His-FLAG-tagged derivative of Ssn8
84 for purification. The activity of Ssn3^{WT} or Ssn3^{AS} was assessed using ³²P *in vitro* kinase
85 assays (20) in which phosphorylation of recombinantly produced C-terminal domain
86 (CTD) of RNA Pol II, an Ssn3 substrate, was monitored. The Ssn3^{WT} and Ssn3^{AS} kinases
87 had equal CTD phosphorylation activity in the absence of inhibitor (**Fig. 1**). The Ssn3^{AS}
88 kinase activity was inhibited by 3-MB-PP1 in a dose-responsive fashion, while addition of
89 this compound had no effect on the Ssn3^{WT} kinase activity (**Fig. 1**). A concentration of 2.7
90 μM 3-MB-PP1 inhibited ~85% of the Ssn3^{AS} activity and 24 μM virtually eliminated the
91 activity.

92 In order to determine if Ssn3 kinase activity could be inhibited *in vivo*, we
93 engineered a derivative of *C. albicans* SC5314 in which both alleles of *SSN3* had been

94 replaced by *ssn3^{AS}*. We also constructed a strain with two copies of the *ssn3-D325A*
95 allele, which encodes a non-functional, or kinase dead, Ssn3 variant (21) due to mutation
96 of a key aspartate in the catalytic site. This kinase-dead variant is referred to here as
97 *ssn3^{KD}*. We have previously shown that, under certain growth conditions, *ssn3 Δ/Δ*
98 mutants form hyperwrinkled colonies compared to the SC5314 wild type (WT) (12), a
99 phenotype associated with increased hyphal growth. Thus, we asked if the Ssn3^{AS}-
100 expressing strain had a hyperfilamentous phenotype specifically in the presence of 3-MB-
101 PP1 and not in its absence. To quantify hypha formation differences in WT, *ssn3^{AS}*, and
102 *ssn3^{KD}* strains, we identified conditions which revealed differences in the propensity for
103 hypha formation among strains. Thus, we grew cells in YNB containing amino acids and
104 N-acetyl-glucosamine (GlcNAc), both of which are inducers of hyphal growth (YNBAG),
105 but incubated cultures at 30°C, a temperature lower than that generally used to induce
106 robust hyphal growth. All cultures were amended with either 3-MB-PP1 or the vehicle
107 DMSO. The morphology of the WT was almost entirely yeast and pseudohyphae, and the
108 relative fractions of these morphologies were unaffected by 5 μ M 3-MB-PP1 (**Fig. 2A**).
109 While the *ssn3^{AS}* cells were similar to the WT in vehicle control cultures, the addition of
110 3-MB-PP1 to *ssn3^{AS}* cultures caused a significant increase in the number of hyphae (**Fig.**
111 **2**). The increase in the fraction of cells in the hyphal morphology in 3-MB-PP1 treated
112 *ssn3^{AS}* was concomitant with a significant decrease in the fraction of cells present as
113 yeast (**Fig. 2A**). The *ssn3^{KD}* strain formed significantly more hyphae than the WT and
114 *ssn3^{AS}* strains in control conditions, and the fraction of cells as hyphae was unaffected by
115 the addition of 3-MB-PP1 (**Fig. 2A-B**). Together, these data indicated that 5 μ M 3-MB-

116 PP1 inhibits Ssn3^{AS} *in vivo* and that the ATP analog has no discernable effects on the
117 morphology of WT or *ssn3^{KD}* strains.

118

119 **Transcriptomics analyses reveal inhibition of Cdk8 by 3-MB-PP1 leads to the**
120 **induction of hypha-specific genes**

121 To further explore the effects of Ssn3 inhibition on the regulation of hypha
122 formation (12) and on transcription more broadly, we examined the transcriptomes of
123 *ssn3^{AS}* and WT strains grown with 3-MB-PP1 or DMSO vehicle. The WT strain was
124 included in this experiment to assess off-target effects of 3-MB-PP1. Cells from stationary
125 phase cultures were inoculated into the same medium used for morphology assessment,
126 YNBAG, with either 5 μ M 3-MB-PP1 or an equivalent volume of DMSO. Three replicate
127 cultures for each strain-treatment combination were incubated for 60 min at 30°C prior to
128 RNA harvest and sequencing as described in the methods. In the *ssn3^{AS}* strain, we found
129 that 249 genes were significantly up regulated upon treatment with 3-MB-PP1 by 2- to
130 49-fold ($p < 0.05$ FDR); transcripts for 33 genes were significantly lower by more than 2-
131 fold with treatment (**Table S2**). Fewer genes were affected by 3-MB-PP1 in the WT with
132 157 and 4 genes significantly increased and decreased, respectively; the magnitudes of
133 the changes were also smaller (2- to 6-fold) (**Table S2**). The greater number of transcripts
134 at higher levels upon inhibition of Ssn3 is consistent with the Cdk8 module being a
135 predominantly negative regulator of transcription factors (3) or the transcriptional re-
136 initiation or “pausing” of RNA polymerase II (reviewed in (22)). We found seventy-seven
137 transcripts that exhibited a significant fold increase (>2-fold) in both the comparison of the
138 *ssn3^{AS}* strain treated with 3-MB-PP1 to its treatment with DMSO, and the comparison of

139 3-MB-PP1-treated *ssn3^{AS}* strain to 3-MB-PP1-treated WT (**Fig. 3** with gene expression
140 shown in log₂-transformed counts per million). Consistent with phenotypic analysis of the
141 effects of Ssn3 inhibition on morphology, transcripts encoding *ECE1* and *HWP1* were two
142 of the most highly induced by Ssn3 inhibition in the AS strain (46- and 22-fold higher,
143 respectively). Other transcripts differentially-increased upon Ssn3 inhibition included
144 genes associated with hyphal morphology, such as *ALS1*, *ALS3*, *IHD1*, *RBT1*, *HYR1*, and
145 *HGC1* (14, 23). Consistent with the previous finding that Ssn3 represses induction of Mrr1
146 controlled genes, *MDR1* was significantly induced with Ssn3 inhibition (11).

147

148 **Specific inhibition of Ssn3 affects the phosphoproteome during the induction of** 149 **hyphal growth**

150 To identify direct phosphorylation targets of Ssn3 that led to changes in phenotype
151 and the transcriptome, we used mass spectrometry to quantitatively analyze the
152 phosphoproteomes of the *ssn3^{AS}* strain compared to the WT after 3-MB-PP1 treatment.
153 We grew *ssn3^{AS}* and WT cells to stationary phase, then incubated culture aliquots with 5
154 μM 3-MB-PP1 for five minutes to allow for drug entry into the cell. We then added
155 concentrated, fresh, pre-warmed YNBAG medium to reproduce the conditions that induce
156 hyphal growth in strains with low Ssn3 activity but not in the WT. Cultures were incubated
157 for an additional 15 min at 30°C with shaking followed by rapid harvest in order to
158 minimize secondary effects of Ssn3 inhibition. Cells were lysed under liquid nitrogen by
159 grinding. We conducted three replicate experiments across three different days, each
160 from an independent overnight culture to increase the robustness of our experimental
161 design.

162 To reveal the direct targets of Ssn3, we focused on phosphosites that became less
163 abundant in the presence of 3-MB-PP1 in the *ssn3^{AS}* strain, but not the WT (**Table 1** and
164 **Table S3** for complete dataset). We found that 977 phosphopeptides mapping to 552
165 proteins were depleted in *ssn3^{AS}* compared to WT, setting a 2-fold cutoff in addition to the
166 $P < 0.05$ test for significance (**Table 1**). Within this group of depleted phosphosites, 82.7%
167 were serines, 15.8% were threonines, and 1.5% were tyrosines. These proportions are
168 very similar to those we observed with a quantification of the whole *C. albicans*
169 phosphoproteome (20), with a slight increase in the number of phosphoserines and a
170 concomitant decrease in the number of phosphothreonines. Although promiscuous, Cdks
171 have been described as proline-directed kinases, and consistent with this, 293
172 phosphopeptides contained prolines in the position adjacent to C-terminal side of the
173 phosphoresidue, referred to as the Proline Motif (**Table 1**) (24). Fewer phosphosites were
174 found within common RXS/T motifs, in which arginine is in the -2 position relative to the
175 phosphoserine or phosphothreonine, (25). We observed that 264 phosphopeptides (202
176 proteins) were significantly enriched upon Ssn3 inhibition. This increase in
177 phosphorylation likely represents indirect or secondary effects of Ssn3 inhibition.

178 We found 218 proteins that contained phosphosites covered by 2 or more depleted
179 phosphopeptides (a consideration taken to increase stringency) in the *ssn3^{AS}* strain
180 compared to WT, and of these 218 proteins, 40 were annotated as having known or
181 predicted nuclear localization in UniProt (**Fig. 4**)(26). Among these, we found that Ssn3^{AS}
182 inhibition led to depletion of phosphopeptides from Med4, with phosphorylated S21 and
183 S33, which is notable as these have previously been identified as target sites for the *C.*
184 *albicans* Ssn3 kinase (20). We also observed depletion of specific phosphosites (T589

185 and S620) in Flo8, a regulator of filamentous growth in both *C. albicans* and *S. cerevisiae*
186 (17, 18, 27), and both T589 and S620 were found within the aforementioned proline motif
187 (**Table 1**). Our transcriptomic data showed that *FLO8* levels were unchanged by either
188 Cdk8 inhibition or 3-MB-PP1 addition (**Table S2**). While we focus on Flo8 in the studies
189 presented here, it is worth noting that other hyphal growth associated transcription
190 factors, such as Efg1 were found among the proteins with phosphosites that were at
191 lower abundance with Ssn3 inhibition as discussed below.

192 **Flo8 is required for Ssn3-dependent hyperfilamentation and hypha-specific gene**
193 **expression.**

194 To determine whether there was a genetic interaction between *SSN3* and *FLO8*
195 that accompanied the phosphoproteomic data above, we investigated the phenotype of
196 single and double null mutants of these two genes. We previously reported that an *ssn3*
197 null mutant forms wrinkled colonies in the presence of a metabolic inhibitor, pyocyanin,
198 while the WT does not (12). While both the *ssn3* null strain and the WT formed smooth
199 colonies on YNBA agar at 30°C (which is the same as YNBAG used above but without
200 GlcNAc), only the *ssn3* Δ/Δ formed wrinkled colonies at 37°C. Similarly, the *ssn3* Δ/Δ strain,
201 but not the WT, formed wrinkled colonies on solid YNBA medium with 110 mM added
202 glucose (**Fig. 5A**). This wrinkled colony phenotype of the *ssn3* Δ/Δ mutant under the above
203 conditions was abolished upon deletion of *FLO8* (*ssn3* Δ/Δ *flo8* Δ/Δ) (**Fig. 5A**). The *flo8* Δ/Δ
204 mutant formed smooth colonies, like the WT, under all conditions. In liquid medium, we
205 observed a similar epistatic relationship between *FLO8* and *SSN3*. Only the *ssn3* Δ/Δ
206 strain, and not the WT, formed hyphae and the hyperfilamentation phenotype in *ssn3* Δ/Δ

207 was dependent on *FLO8* (**Fig. 5B**). Expression levels of hypha-specific transcripts that
208 were induced upon inhibition of Ssn3^{AS} (**Fig. 3**) were significantly higher in the *ssn3Δ/Δ*
209 background compared to the WT, but not in the *ssn3Δ/Δflo8Δ/Δ* background (**Fig. 5C**). In
210 **Fig. 6**, we demonstrate the ability to complement the filamentation defects of the *flo8Δ/Δ*
211 and *ssn3Δ/Δflo8Δ/Δ* with the native *FLO8* allele, and this result is described in more detail
212 below.

213 We also found that the *ssn3Δ/Δ* strain was hyperfilamentous in comparison to the
214 WT in embedded conditions, and that deletion of *FLO8* in the *ssn3Δ/Δ* background was
215 able to suppress this phenomenon (**Fig. 5D**). Cao et al. (17) reported that *FLO8* was
216 necessary for embedded filamentation and we reproduced this result (**Fig. 5D**). To
217 determine whether *FLO8* is also required for embedded hyphal growth in *efg1Δ/Δ*, another
218 strain that is hyperfilamentous under embedded conditions (28, 29), we generated a *flo8*
219 and *efg1* null double mutant. We found that *FLO8* disruption suppressed embedded
220 filamentation in the *efg1Δ/Δ* background (**Fig. S1A**).

221 **Loss of putative Ssn3-phosphosites in Flo8 leads to increased filamentation**

222 To study the effects of Ssn3 activity on Flo8 protein, we complemented the
223 *ssn3Δ/Δflo8Δ/Δ* mutant with an allele that encodes a 3XHA-Flo8. This allele restored the
224 hyperfilamentous *ssn3Δ/Δ* phenotype to the *ssn3Δ/Δflo8Δ* strain (**Fig. 6A**). To further
225 explore the effects of Flo8 phosphorylation by Ssn3, we generated an allele in which both
226 T589 and S620, the sites identified in the phosphoproteomics analysis of the Ssn3^{AS}
227 bearing strain, were mutated to alanines (a phospho-incompetent residue) or glutamic
228 acid (which also abolishes phosphorylation, but sometimes can serve as a

229 phosphomimetic) to determine whether these residues play roles in the morphological
230 phenotype of Cdk8 inhibition. Neither the WT or *flo8Δ/Δ* strain gave a wrinkled colony
231 morphology on either medium (**Fig. 6A**) and, as expected, complementation of the *flo8Δ/Δ*
232 with epitope tagged Flo8 did not change colony morphology. However, complementing
233 the *flo8Δ/Δ* strain with either *flo8^{T589A, S620A}* or *flo8^{T589E, S620E}* led to a wrinkled colony
234 phenotype in the presence 110 mM glucose, suggesting that the phosphorylation of Flo8,
235 potentially via Ssn3, represses Flo8 activity and that the absence of these sites releases
236 that repression (**Fig. 6A**). Consistent with the increased wrinkled colony phenotype in the
237 *flo8Δ/Δ* strains with *flo8^{T589A, S630A}* or *flo8^{T589E, S620E}* relative to the strain with unmutated
238 *FLO8*, both Flo8 variants also led to increased hyphal development in YNBAG (**Fig. 6B**).
239 Because both *flo8^{T589A, S620A}* and *flo8^{T589E, S620E}* alleles conferred increased filamentation
240 phenotypes consistent with high Flo8 activity in *flo8Δ/Δ* and *ssn3Δ/Δflo8Δ/Δ* strains we
241 concluded that the Flo8^{T589E,S620E} variant was not acting as a phosphomimetic, but rather
242 both had phenotypes consistent with decreased negative regulation. To quantitatively
243 assess the differences in activity of the morphology program attributed to the loss of
244 putative Ssn3 phosphorylation sites, levels of hypha-associated transcripts were
245 measured in the *flo8Δ/Δ* strains with either HA-tagged *FLO8* or *flo8^{T589A, S620A}* (**Fig. 6C**).
246 We found significantly increased expression levels of several core filamentation response
247 genes in the strain with *flo8^{T589A, S620A}* versus that with *FLO8*.

248 In multiple instances, phosphorylation by Ssn3 leads to decreased levels of
249 transcription factors (6, 8, 15). Thus, we tested the hypothesis that Flo8-HA^{T589A,S620A} and
250 Flo8-HA^{T589E,S620E} were present at higher levels than Flo8-HA. We found that indeed the
251 two variants were present at higher relative levels compared to Flo8-HA in an *SSN3* wild-

252 type background. Furthermore, Flo8-HA levels were higher in an *ssn3Δ/Δ* strain than in
253 the *SSN3/SSN3* (+/+) strain which no significant differences in levels for the native and
254 variant proteins. In order to address the slight difference in migration of Flo8-HA in the
255 Δ/Δ strain backgrounds (**Fig. 6D**), we analyzed the migration of FLO8-HA in backgrounds
256 with active Ssn3 (WT and *ssn3^{AS}*) and strains lacking Ssn3 activity (*ssn3Δ/Δ* and *ssn3^{KD}*)
257 (**Fig. 6E**). We confirmed that in the absence of Ssn3 activity, Flo8 migration was slightly
258 faster suggesting that other post-translational modifications (e.g. additional
259 phosphorylations) are controlled by Ssn3. It is worth noting that one other Flo8
260 phosphosite was identified, but it did not reach the significance cutoff.

261

262 **Ssn3 metabolic hyperalkalinization phenotype depends on Flo8**

263 Previous work has shown that the *C. albicans* *ssn3Δ/Δ* mutant differed from the
264 WT in glycolysis and the utilization of amino acids (12). By analyzing the differentially
265 abundant transcripts upon inhibition of Ssn3, we identified statistical enrichment of genes
266 in KEGG pathways involved in amino acid metabolism and glycolysis (**Table S4**). These
267 pathways could represent a potential connection between the *ssn3Δ/Δ* hyperalkalinization
268 phenotype which is dependent on amino acid catabolism and concomitant release of
269 ammonia (12). When grown on amino acid-containing YNBA, alkalization of the agar
270 medium, evident by the color change of the pH indicator, by the *ssn3Δ/Δ* mutant was less
271 sensitive than WT to inhibition caused by increasing glucose concentrations which leads
272 to production of acidic fermentation products. The previously observed alkalization of
273 the medium by the *ssn3Δ/Δ* strain (12) is consistent with increased alkalization due to
274 amino acid catabolism. To determine whether Ssn3 influences medium alkalization

275 through this mechanism, we constructed a *ssn3Δ/Δstp2Δ/Δ* double mutant. Stp2 is a
276 transcription factor involved in ammonia release from amino acid catabolism and is a
277 downstream component of the SPS system (30). *STP2* disruption resulted in a defect in
278 alkalization at 5.5 mM glucose compared to WT and suppressed the hyperalkalinization
279 phenotype of the *ssn3Δ/Δ* strain at both 27.5 mM and 110 mM glucose (**Fig. 7A**). This is
280 consistent with a model in which the SPS amino acid sensing pathway and subsequent
281 generation of ammonium through amino acid catabolism are primarily responsible for the
282 hyperalkalinization phenotype of *SSN3* inactivation.

283 *FLO8* was required for the hyperalkalinization phenotype of the *ssn3Δ/Δ* strain and
284 the phenotype was complemented by reintroducing *FLO8* (**Fig. 7B**), a result that
285 paralleled the Flo8 requirement for hyperfilamentation in the *ssn3Δ/Δ* strain. In contrast,
286 the *flo8Δ/Δ* strain did not differ from the WT in its effects on medium pH, suggesting that
287 Flo8 effects on medium pH were associated with decreased Ssn3 activity (**Fig. 7A**). While
288 complementation of the *ssn3Δ/Δflo8Δ/Δ* double mutant with the wild-type *FLO8* allele
289 restored the metabolic phenotypes, complementation with either *flo8^{T589A,S620A}* or
290 *flo8^{T589E,S620E}* did not exacerbate the phenotype further. Similarly, complementation of the
291 *flo8Δ/Δ* single mutant with the Flo8 variants did not generate changes in alkalization
292 compared to complementation with the native allele suggesting that Ssn3 effects on
293 metabolism may require other factors directly or indirectly regulated by Ssn3.

294

295 **Discussion:**

296 In this work, we used strains with an analog-sensitive *ssn3* allele, a catalytically
297 inactive *ssn3* allele and null mutants to assess how Ssn3 and its kinase activity regulate

298 hyphal growth and metabolism. We identified 754 proteins with significant, differential
299 phosphorylation (>2-fold, $p < 0.05$) upon inhibition of Ssn3 during the yeast to hypha
300 transition and they included Med4, a known Ssn3 substrate, and Flo8, a known regulator
301 of hyphal growth (17, 18). We show that in a variety of conditions, the loss or decrease in
302 Ssn3 activity leads to increased hypha formation and hypha-specific gene expression and
303 that both phenotypes were dependent on Flo8. Through mutagenesis of the two Ssn3
304 phosphorylation sites (T589 and S620), we found that mutation of these sites was
305 sufficient to increase filamentation and hypha-associated gene expression, supporting
306 the model that Ssn3 is a negative regulator of Flo8. Interestingly, deletion of the *S.*
307 *cerevisiae* histone methyltransferase *JHD2* and *SSN8* results in constitutive filamentous
308 growth that requires the transcriptional positive regulator of invasive growth, *FLO8* (10).
309 Our finding of 288 transcripts meeting our criteria for a statistically significant change in
310 abundance upon the inhibition of Ssn3 is similar to the finding of Holstege and colleagues
311 (7, 31) in which microarray analyses in *S. cerevisiae* found ~3% of genes changed by
312 their criteria. The effects of the Ssn3^{AS} variant were modest compared to the effects of
313 Ssn3 inhibition indicating the utility of this variant for the study of short term effects of
314 Ssn3 inhibition.

315 In addition to Flo8, numerous of other transcriptional regulators of morphology
316 have been described including Efg1, Cph1 (a homolog of *S. cerevisiae* Ste12, a known
317 Ssn3 target), Tec1, Ndt80, and Ume6, and repressors like Tup1 and Nrg1 (32-39). Of
318 these, Efg1 and Ndt80 were found to have significantly depleted phosphopeptides upon
319 Ssn3 inhibition. We prioritized Flo8 because Wartenberg, *et al.* (14) recovered
320 filamentation in a macrophage-evolved strain with *ssn3*^{R352N} in an *efg1/cph1* null strain

321 background, suggesting that regulators other than these were active upon changes in
322 Cdk8 activity. Further, we showed that in embedded growth assays, the
323 hyperfilamentation phenotype in both the *ssn3* and *efg1* null backgrounds required Flo8,
324 underscoring the importance of Flo8 in Efg1-independent filamentation. Identification and
325 functional characterization of phosphorylation sites and the understanding of their roles
326 in Ssn3 regulation of activity merits further investigation. Flo8 has been implicated in the
327 transcriptional regulation of true hyphal growth in *C. albicans*, with Flo8, and its binding
328 partner Mss11, both having been described to directly bind the Hyphal Control Region in
329 the promoter of *HWP1*, one of the most strongly differentially abundant transcripts in our
330 transcriptomic data, and Flo8 is thought to be downstream of PKA (27, 40, 41). Ssn3 may
331 play an important role in coordinating the response of multiple regulators during the
332 induction and repression of filamentation. A recent study identified Ssn3 dependent
333 phosphorylation of the transcription factor Ume6 and its degradation, under conditions of
334 hypoxia and atmospheric CO₂, as one way in which the kinase can impact filamentation
335 (15). The absence of Ume6 phosphopeptides in our could be due to differences in kinetics
336 of Flo8 and Ume6 or differences in the technologies used.

337 In addition to hyperfilamentation, wrinkled colony formation and medium
338 alkalinization are phenotypes associated with *ssn3* deletion. As for hyperfilamentous
339 growth, deletion of *FLO8* suppressed the hyperalkalinization phenotype of the *ssn3Δ/Δ*
340 strain. Additionally, we were able to establish a role for Ssn3 upstream of the metabolic
341 regulator Stp2 as deletion of *STP2* in the *ssn3* background was able to almost completely
342 ablate the hyperalkalinization phenotype of the *ssn3Δ/Δ*. Stp2-mediated medium
343 alkalinization is a mechanism by which *C. albicans* can regulate its morphology thus our

344 findings are consistent with a model in which Ssn3 has both direct (Flo8-mediated) and
345 indirect (Stp2-mediated) roles in determining morphology (42).

346 Several other pathways were identified as being influenced by Ssn3 in the
347 proteomics studies including MAP kinase pathways, protein synthesis and chromatin
348 regulation. It is interesting to note that studies of the human Cdk8 have also implicated it
349 in regulating MAPK pathways (43). Notably, many of the phosphoproteins impacted by
350 our inhibition of Ssn3 are not canonically nuclear, suggesting that Cdk8 may have a
351 cytosolic role. This is in agreement with the work of Chen and Noble who identified a role
352 of Cdk8 in the cytosolic phosphorylation of Sef1 (21). As an aside, we did not observe
353 Sef1 phosphopeptides, a documented Ssn3 phosphotarget, and we speculate that this is
354 due to the fact that our experiments were performed in an iron-replete medium which
355 suppresses this phosphorylation event (21). We observed changes in proteins within MAP
356 kinase cascades, their regulators, and effectors, and notable within that classification was
357 the Hog1 MAP kinase pathway (**Table S3**). Among the depleted phosphopeptides in the
358 *ssn3^{AS}* strain were Ssk2 and Pbs2, the MAPKKK and MAPKK, respectively, of the Hog1
359 pathway, but Hog1 itself was not identified as being changed upon inhibition of Ssn3
360 activity. We also found differences in ribosomal biogenesis and protein synthesis. Lastly,
361 we found that phosphopeptides involved in the remodeling of chromatin, such as the Set3
362 histone deacetylase, were depleted upon inhibition of Cdk8 kinase activity. This is similar
363 to a phosphoproteomic study in human cells that identified elements of the NuA3 and
364 NuA4 histone acetyltransferase complex amongst the depleted phosphopeptides upon
365 inhibition of Cdk8 and the related kinase Cdk19 by cortistatin A (44). Set3 is also involved
366 in morphological determination, with a *set3* null mutant displaying a hyperfilamentous

367 phenotype (45). Additionally, it has been found that alterations in chromatin architecture
368 participate in the interplay between Nrg1 and hypha-specific gene expression (39). The
369 existence of a substantial suite of proteins involved in chromatin remodeling that show
370 decreased phosphorylation with Ssn3 inhibition in the phosphoproteomic results is also a
371 possible mechanism to account for the hyphal morphology phenotype of Ssn3 inhibition.
372 A potential hypothesis is that Cdk8 phosphorylates hyphal transcriptional regulators like
373 Flo8 acting in concert with phosphorylation of elements of the chromatin remodeling
374 machinery, which promotes the formation of repressive chromatin structures at hypha-
375 associated genes.

376 Unlike some other components of Mediator, which have pleiotropic effects on
377 transcription, the role of the Cdk8 sub-module seems to be specific to certain
378 developmental and nutrient regulated pathways across eukarya (22). This more
379 specialized role has made Cdk8 a potential drug target for several diseases. For
380 example, inhibitors of mammalian Cdk8 have been extensively explored as potential
381 cancer therapies (46). As cancer therapeutics are often administered in the context of
382 immunosuppression, it is important to understand the impact of these compounds on *C.*
383 *albicans*, since inhibition of Ssn3 could potentiate or attenuate the virulence of this
384 opportunistic pathogen.

385

386 **Materials and Methods**

387 *Media and growth conditions:* Strains were maintained on YPD plates, and overnight
388 cultures for morphology and RNA seq were grown in YNB/1% glucose at 30°C in culture
389 tubes on a roller drum. YPD plates were routinely streaked from glycerol stocks, and

390 experiments were only conducted with overnight cultures from plates not more than 5
391 days old. YNB medium with 2% (w/v) casamino acids and 11 mM glucose (YNBAG) with
392 or without 5 mM N-acetyl glucosamine (GlcNAc) was adjusted to pH 5.1 (morphology and
393 RNA seq experiments) or pH 6.0 (phosphoproteomics) with concentrated hydrochloric
394 acid, and filter sterilized. When indicated, the pH indicator bromocresol purple was
395 included in the medium as described in (12). Additional medium, temperature, and
396 incubation time details pertaining to morphology assessments can be found in the
397 corresponding figure legends.

398

399 *Wrinkled colony and alkalization assays:* Overnight cultures (YPD) of each strain were
400 washed once with water and diluted to OD₆₀₀ 4. 8 μ L of cell suspension was spotted onto
401 the indicated medium. Images were typically taken after 2 days growth at 37°C or 3 days
402 growth at 30°C. For alkalization assays, 2X YNB based media was adjusted to pH 5.0
403 by HCl, filter sterilized and mixed with autoclaved 4% agar solution. Bromocresol purple
404 (BCP) was added to 0.01% from a 0.1% aqueous stock into the media before 2 mL was
405 aliquoted into each well of a 24-well plate. pH references were generated using YNB
406 media buffered by phosphate buffer (20 mM) with known pH.

407

408 *Strain construction:* All strains used in this study are listed in Table S1. Primers and
409 plasmid sequences are available upon request. Strains expressing analog-sensitive and
410 kinase-dead Ssn3 variants, referred to as *ssn3^{AS}* and *ssn3^{KD}*, respectively, were
411 generated by transformation of SC5314 with a DNA fragment containing *ssn3-F257G*
412 (*ssn3^{AS}*) or *ssn3^{D325A}* (*ssn3^{KD}*) adjacent to the SAT-FLP cassette directed to the *SSN3*

413 locus. These constructs were transformed alongside the *Candida*-optimized
414 CRISPR/Cas9 machinery and a guide sequence targeting the nuclease to the *SSN3* open
415 reading frame (47). Transformants were selected on YPD with 200 µg neourseothricin
416 (GoldBio). Resistant colonies were patched onto YPD with 200 µg neourseothricin. No
417 homozygous mutant transformants were identified, likely due to the guide sequence
418 targeting the CRISPR/Cas9 nuclease to the mutant repair template. However, there were
419 transformants likely for the intended point mutation (assayed with Sanger sequencing)
420 which probably came about due to CRISPR-independent allelic replacement by
421 homologous recombination in cells that did not also take up the Cas9 machinery.
422 Amplification using primers that spanned the *SSN3* locus from DNA isolated from these
423 heterozygotes revealed the *SAT1* marker was excised during outgrowth on YPD.
424 Transformants were purified to single colonies, and neourseothricin sensitivity was
425 confirmed by patching on YPD plates containing 200 µg per mL neourseothricin.
426 Heterozygous point mutants underwent a second transformation with the same construct
427 using the methods described above to generate homozygotes. Transformants in both
428 rounds of transformation were confirmed by PCR amplifying a ≈970 base pair internal
429 region of *SSN3* covering the region encoding residues 257 and 325 using primers Ssn3
430 Internal FWD and Ssn3 Internal Rev, and Sanger sequencing with the reverse primer. As
431 in the first round, a number of these transformants had excised the resistance marker as
432 observed by PCR during outgrowth on neourseothricin plates, and these sensitive
433 homozygotes were purified to single colonies. Generation of subsequent knockout
434 mutants was carried out using a previously described transient CRISPR-Cas9 system
435 using a SAT-flipper selection marker (48). To generate double mutants, the *SAT1*

436 cassette was recycled by inducing flippase expression in YP maltose (1% yeast extract,
437 2% peptone, 2% maltose) for 24 hours. Generation of HA-tagged flo8-bearing strains
438 was similarly accomplished through a repair construct in which the desired allele was
439 fused to the SAT-FLP marker.

440

441 *Mediator purification and in vitro kinase assays:* Ssn8-tagged Mediator containing various
442 Cdk8 alleles was purified and used for *in vitro* kinase assays with a GST-CTD substrate
443 as previously described (20, 49). Amounts of the kinase were normalized by the signal
444 on the FLAG tag.

445

446 *Analysis of C. albicans morphology:* Morphological assessment was conducted in
447 YNB_{NAG11} at 30°C. For the analysis of the effects of 3-MB-PP1 (the ATP analog used
448 to inhibit analog-sensitive kinases), cells grown overnight at 30°C in YNB with 1% (w/v)
449 glucose were pelleted by centrifugation and resuspended in 5 mL YNB_{NAG11} pH 5.1
450 containing 5 µM 3-MB-PP1 (EMD MILLIPORE) or DMSO as a vehicle control. The cells
451 were then incubated at 30°C for 3h in culture tubes on a roller drum, fixed in
452 formaldehyde, and morphology quantified from image captured using differential
453 interference contrast microscopy. Cells were considered to be true hyphae if germ tubes
454 had parallel sides and no invagination at the junction of the filament and the mother
455 blastospore. A minimum of 175 cells per replicate were counted, and data presented
456 represent three independent biological replicates conducted on three different days.
457 Cultures were inoculated to an initial density of 1x10⁷ cells per mL.

458

459 *Analysis of the C. albicans transcriptome upon Ssn3 inhibition using RNA seq:* Cells were
460 grown as described above for morphological assessment, but the incubation time was
461 reduced to decrease indirect effects of Ssn3 inhibition. Specifically, the time following
462 drug exposure was reduced from three hours to one hour. The 5 mL cultures were
463 collected one hour after 3-MB-PP1 addition, pelleted by centrifugation, snap frozen in
464 liquid nitrogen, and RNA was isolated with the MasterPure™ Yeast RNA Purification Kit
465 (Epicentre MPY03100). For RNA sequencing, 500 ng of total RNA was input into the Kapa
466 mRNA HyperPrep kit (Kapa Biosystems, Wilmington, MA) and processed according to
467 the manufacturer's instructions. All 24 samples were multiplexed together into a single
468 High Output 2x75bp run on a NextSeq 500 instrument (Illumina, San Diego, CA). Raw
469 reads were mapped to the *C. albicans* genome SC5314 (version A21-s02-m09-r04,
470 candidagenome.org), and normalized using EdgeR. KEGG enrichment analysis was
471 carried out using KOBAS 2.0 (50).

472
473 RNA was extracted from frozen cell pellets as described (51). Data were presented after
474 normalization by geometric mean of positive controls and geometric mean of *TEF1* and
475 *ACT1* reads. Gene expression in a wild-type strain or a *flo8* mutant was set to '1' as
476 mentioned in the figure legends. The accession number for the data is GSE171859.
477 During the review phase, RNA Seq data can be accessed at
478 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE171859> and the access token
479 is mpsfuucityvtreh. The data will be publicly available upon acceptance for publication.

480

481 *Ssn3 phosphoproteomic experimental design:* 300 mL YNB_{NAG}₁₁ (pH 6.0) cultures of
482 SC5314 and *ssn3^{AS}* were inoculated at a density of OD₆₀₀ of 0.01 and grown to OD₆₀₀ of
483 4.5 in flasks with shaking at 30°C, then incubated for a subsequent 4.5 hours to ensure
484 cells had entered stationary phase. Stationary phase cells were incubated in the presence
485 of 5 μM 3-MB-PP1 for five minutes to enable drug entry into the cell. The cells were then
486 concentrated and added to fresh, pre-warmed medium containing either drug or vehicle
487 and incubated for 15 minutes at 30°C with shaking. Either DMSO vehicle or 5 μM 3-MB-
488 PP1 was then added, after which cultures were incubated with shaking for five minutes
489 at 30°C. Then, 1.2 L of prewarmed fresh YNB_{NAG}₁₁ (pH 6.0) medium was added as a
490 1.25X concentrate, and cells were incubated for an additional 15 minutes. The cells were
491 then harvested by centrifugation and cell lysis by grinding under liquid nitrogen. All growth
492 and incubation steps were conducted at 30°C, and the data represent the average of
493 three independent replicates conducted on three separate days.

494
495 *Phosphoproteomic analysis.* Yeast powder was lysed in ice-cold lysis buffer ((8 M urea,
496 25 mM Tris-HCl pH 8.6, 150 mM NaCl, phosphatase inhibitors (2.5 mM beta-
497 glycerophosphate, 1 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM sodium
498 molybdate) and protease inhibitors (1 mini-Complete EDTA-free tablet per 10 ml lysis
499 buffer; Roche Life Sciences)) and sonicated three times for 15 sec each with intermittent
500 cooling on ice. Lysates were centrifuged at 15,000 x *g* for 30 minutes at 4°C. Supernatants
501 were transferred to a new tube and the protein concentration was determined using a
502 BCA assay (Pierce-ThermoFisher Scientific). For reduction, DTT was added to the
503 lysates to a final concentration of 5 mM and incubated for 30 min at 55°C. Afterwards,

504 lysates were cooled to room temperate and alkylated with 15 mM iodoacetamide at room
505 temperature for 45 min. The alkylation was then quenched by the addition of an additional
506 5 mM DTT. After 6-fold dilution with 25 mM Tris-HCl pH 8, the samples were digested
507 overnight at 37°C with 1:100 (w/w) trypsin. The next day, the digest was stopped by the
508 addition of 0.25% TFA (final v/v), centrifuged at 3500 x g for 30 minutes at room
509 temperature to pellet precipitated lipids, and peptides were desalted on a 500 mg (sorbent
510 weight) SPE C₁₈ cartridge (Grace-Davidson). Peptides were lyophilized and stored at -
511 80°C until needed for future use.

512

513 *Phosphopeptide enrichment.* Phosphopeptide purification was performed as previously
514 described (52). Briefly, peptides were resuspended in 1.5 M lactic acid in 50% ACN
515 (“binding solution”). Titanium dioxide microspheres were added and vortexed by affixing
516 to the top of a vortex mixer on the highest speed setting at room temperature for 1 hour.
517 Afterwards, microspheres were washed twice with binding solution and three times with
518 50% ACN / 0.1% TFA. Peptides were eluted twice with 50 mM KH₂PO₄ (adjusted to pH
519 10 with ammonium hydroxide). Peptide eluates were combined, quenched with 50% ACN
520 / 5% formic acid, dried and desalted on a µHLB OASIS C₁₈ desalting plate (Waters).
521 Phosphopeptide enrichment was repeated once.

522

523 *TMT-labeling.* Phosphopeptides were resuspended in 133 mM HEPES (Sigma) pH 8.5
524 and 20% acetonitrile (ACN) (Burdick & Jackson). Peptides were transferred to dried,
525 individual TMT reagent (ThermoFisher Scientific), and vortexed to mix reagent and
526 peptides. After 1 hr at room temperature, each reaction was quenched with 3 µl of 500

527 mM ammonium bicarbonate solution for 10 minutes, mixed, diluted 3-fold with 0.1% TFA
528 in water, and desalted using C₁₈ solid phase extraction cartridges (ThermoFisher
529 Scientific). The desalted multiplexes were dried by vacuum centrifugation.

530

531 *Pentafluorophenyl-based Reversed Phase HPLC*. Offline PFP-based reversed phase
532 HPLC fractionation was performed as previously described (53). Briefly, phosphopeptides
533 were fractionated using a Waters XSelect HSS PFP 2.5 µm 2.1 × 150 mm column on an
534 Agilent 1100 liquid chromatography system, buffer A was 3% acetonitrile / 0.1% TFA, and
535 buffer B was 95% acetonitrile / 0.1% TFA. Flow rate was 150 µl/min with a constant
536 column temperature of 20°C. Phosphopeptides were fractionated using a 60-minute linear
537 gradient from 8-45% acetonitrile and collected as 48 fractions between minutes 2 and 65.
538 The 48 fractions were then combined into 24 total samples.

539

540 *TMT-based quantitative data analysis* TMT-labeled samples were analyzed on a Orbitrap
541 Fusion (Senko, Remes et al. 2013) mass spectrometer (ThermoScientific) equipped with
542 an Easy-nLC 1000 (ThermoScientific). Peptides were resuspended in 8% methanol / 1%
543 formic acid across a column (45 cm length, 100 µm inner diameter, ReproSil, C₁₈ AQ 1.8
544 µm 120 Å pore) pulled in-house across a 2 h gradient from 8% acetonitrile/0.0625% formic
545 acid to 37% acetonitrile/0.0625% formic acid. The Orbitrap Fusion was operated in data-
546 dependent, SPS-MS3 quantification mode (54, 55) wherein an Orbitrap MS1 scan was
547 taken (scan range = 350 – 1500 m/z, R = 120K, AGC target = 2.5e5, max ion injection
548 time = 100 ms), followed by ion trap MS2 scans on the most abundant precursors for 4

549 seconds (max speed mode, quadrupole isolation = 0.6 m/z, AGC target = 4e3, scan rate
550 = rapid, max ion injection time = 60 ms, minimum MS1 scan signal = 5e5 normalized
551 units, charge states = 2, 3 and 4 included, CID collision energy = 33%) and Orbitrap MS3
552 scans for quantification (R = 15K, AGC target = 2e4, max ion injection time = 125 ms,
553 HCD collision energy = 48%, scan range = 120 – 140 m/z, synchronous precursors
554 selected = 10). The raw data files were searched using COMET with a static mass of
555 229.162932 on peptide N-termini and lysines and 57.02146 Da on cysteines, and a
556 variable mass of 15.99491 Da on methionines and 79.96633 Da on serines, threonines
557 and tyrosine against the target-decoy version of the respective FASTA database (UniProt;
558 www.uniprot.org) and filtered to a <1% FDR at the peptide level. Quantification of LC-
559 MS/MS spectra was performed using software developed in house. Phosphopeptide
560 intensities were adjusted based on total TMT reporter ion intensity in each channel and
561 log₂ transformed. P-values were calculated using a two tailed Student's t-test assuming
562 unequal variance.
563

564 **References:**

565

566 1. Dannappel MV, Sooraj D, Loh JJ, Firestein R. 2018. Molecular and in vivo
567 functions of the CDK8 and CDK19 kinase modules. *Front Cell Dev Biol* 6:171.

568 2. Youn DY, Xiaoli AM, Pessin JE, Yang F. 2016. Regulation of metabolism by the
569 Mediator complex. *Biophys Rep* 2:69-77.

570 3. Galbraith MD, Andrysik Z, Pandey A, Hoh M, Bonner EA, Hill AA, Sullivan KD,
571 Espinosa JM. 2017. CDK8 kinase activity promotes glycolysis. *Cell Rep* 21:1495-
572 1506.

573 4. Bancerek J, Poss ZC, Steinparzer I, Sedlyarov V, Pfaffenwimmer T, Mikulic I,
574 Dolken L, Strobl B, Muller M, Taatjes DJ, Kovarik P. 2013. CDK8 kinase
575 phosphorylates transcription factor STAT1 to selectively regulate the interferon
576 response. *Immunity* 38:250-62.

577 5. Zhao X, Feng D, Wang Q, Abdulla A, Xie XJ, Zhou J, Sun Y, Yang ES, Liu LP,
578 Vaitheesvaran B, Bridges L, Kurland IJ, Strich R, Ni JQ, Wang C, Ericsson J,
579 Pessin JE, Ji JY, Yang F. 2012. Regulation of lipogenesis by cyclin-dependent
580 kinase 8-mediated control of SREBP-1. *J Clin Invest* 122:2417-27.

581 6. Rohde JR, Trinh J, Sadowski I. 2000. Multiple signals regulate GAL transcription
582 in yeast. *Mol Cell Biol* 20:3880-6.

- 583 7. Holstege FC, Jennings EG, Wyrick JJ, Lee TI, Hengartner CJ, Green MR, Golub
584 TR, Lander ES, Young RA. 1998. Dissecting the regulatory circuitry of a eukaryotic
585 genome. *Cell* 95:717-28.
- 586 8. Nelson C, Goto S, Lund K, Hung W, Sadowski I. 2003. Srb10/Cdk8 regulates yeast
587 filamentous growth by phosphorylating the transcription factor Ste12. *Nature*
588 421:187-90.
- 589 9. Raithatha S, Su TC, Lourenco P, Goto S, Sadowski I. 2012. Cdk8 regulates
590 stability of the transcription factor Phd1 to control pseudohyphal differentiation of
591 *Saccharomyces cerevisiae*. *Mol Cell Biol* 32:664-74.
- 592 10. Law MJ, Ciccaglione K. 2015. Fine-tuning of histone H3 Lys4 methylation during
593 pseudohyphal differentiation by the CDK submodule of RNA polymerase II.
594 *Genetics* 199:435-53.
- 595 11. Liu Z, Myers LC. 2017. *Candida albicans* Swi/Snf and Mediator complexes
596 differentially regulate Mrr1-induced *MDR1* expression and fluconazole resistance.
597 *Antimicrob Agents Chemother* 61.
- 598 12. Lindsay AK, Morales DK, Liu Z, Grahl N, Zhang A, Willger SD, Myers LC, Hogan
599 DA. 2014. Analysis of *Candida albicans* mutants defective in the Cdk8 module of
600 mediator reveal links between metabolism and biofilm formation. *PLoS Genet*
601 10:e1004567.

- 602 13. Grahl N, Demers EG, Lindsay AK, Harty CE, Willger SD, Piispanen AE, Hogan
603 DA. 2015. Mitochondrial activity and Cyr1 are key regulators of Ras1 activation of
604 *C. albicans* virulence pathways. PLoS Pathog 11:e1005133.
- 605 14. Wartenberg A, Linde J, Martin R, Schreiner M, Horn F, Jacobsen ID, Jenull S, Wolf
606 T, Kuchler K, Guthke R, Kurzai O, Forche A, d'Enfert C, Brunke S, Hube B. 2014.
607 Microevolution of *Candida albicans* in macrophages restores filamentation in a
608 nonfilamentous mutant. PLoS Genet 10:e1004824.
- 609 15. Lu Y, Su C, Ray S, Yuan Y, Liu H. 2019. CO₂ signaling through the Ptc2-Ssn3
610 axis governs sustained hyphal development of *Candida albicans* by reducing
611 Ume6 phosphorylation and degradation. mBio 10.
- 612 16. Liu Y, Kung C, Fishburn J, Ansari AZ, Shokat KM, Hahn S. 2004. Two cyclin-
613 dependent kinases promote RNA polymerase II transcription and formation of the
614 scaffold complex. Mol Cell Biol 24:1721-35.
- 615 17. Cao F, Lane S, Raniga PP, Lu Y, Zhou Z, Ramon K, Chen J, Liu H. 2006. The Flo8
616 transcription factor is essential for hyphal development and virulence in *Candida*
617 *albicans*. Mol Biol Cell 17:295-307.
- 618 18. Polvi EJ, Veri AO, Liu Z, Hossain S, Hyde S, Kim SH, Tebbji F, Sellam A, Todd
619 RT, Xie JL, Lin ZY, Wong CJ, Shapiro RS, Whiteway M, Robbins N, Gingras AC,
620 Selmecki A, Cowen LE. 2019. Functional divergence of a global regulatory
621 complex governing fungal filamentation. PLoS Genet 15:e1007901.

- 622 19. Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, Blethrow J, Shimizu
623 E, Tsien JZ, Schultz PG, Rose MD, Wood JL, Morgan DO, Shokat KM. 2000. A
624 chemical switch for inhibitor-sensitive alleles of any protein kinase. *Nature*
625 407:395-401.
- 626 20. Willger SD, Liu Z, Olarte RA, Adamo ME, Stajich JE, Myers LC, Kettenbach AN,
627 Hogan DA. 2015. Analysis of the *Candida albicans* phosphoproteome. *Eukaryot*
628 *Cell* 14:474-85.
- 629 21. Chen C, Noble SM. 2012. Post-transcriptional regulation of the Sef1 transcription
630 factor controls the virulence of *Candida albicans* in its mammalian host. *PLoS*
631 *Pathog* 8:e1002956.
- 632 22. Allen BL, Taatjes DJ. 2015. The Mediator complex: a central integrator of
633 transcription. *Nat Rev Mol Cell Biol* 16:155-66.
- 634 23. Martin R, Albrecht-Eckardt D, Brunke S, Hube B, Hunniger K, Kurzai O. 2013. A
635 core filamentation response network in *Candida albicans* is restricted to eight
636 genes. *PLoS One* 8:e58613.
- 637 24. Malumbres M. 2014. Cyclin-dependent kinases. *Genome Biol* 15:122.
- 638 25. Kemp BE, Graves DJ, Benjamini E, Krebs EG. 1977. Role of multiple basic
639 residues in determining the substrate specificity of cyclic AMP-dependent protein
640 kinase. *J Biol Chem* 252:4888-94.

- 641 26. UniProt C. 2019. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids*
642 *Res* 47:D506-D515.
- 643 27. Liu H, Styles CA, Fink GR. 1996. *Saccharomyces cerevisiae* S288C has a
644 mutation in FLO8, a gene required for filamentous growth. *Genetics* 144:967-78.
- 645 28. Doedt T, Krishnamurthy S, Bockmuhl DP, Tebarth B, Stempel C, Russell CL,
646 Brown AJ, Ernst JF. 2004. APSES proteins regulate morphogenesis and
647 metabolism in *Candida albicans*. *Mol Biol Cell* 15:3167-80.
- 648 29. Saputo S, Kumar A, Krysan DJ. 2014. Efg1 directly regulates *ACE2* expression to
649 mediate cross talk between the cAMP/PKA and RAM pathways during *Candida*
650 *albicans* morphogenesis. *Eukaryot Cell* 13:1169-80.
- 651 30. Miramon P, Pountain AW, van Hoof A, Lorenz MC. 2020. The Paralogous
652 Transcription Factors Stp1 and Stp2 of *Candida albicans* Have Distinct Functions
653 in Nutrient Acquisition and Host Interaction. *Infect Immun* 88.
- 654 31. van de Peppel J, Kettelarij N, van Bakel H, Kockelkorn TT, van Leenen D, Holstege
655 FC. 2005. Mediator expression profiling epistasis reveals a signal transduction
656 pathway with antagonistic submodules and highly specific downstream targets.
657 *Mol Cell* 19:511-22.
- 658 32. Schweizer A, Rupp S, Taylor BN, Rollinghoff M, Schroppel K. 2000. The
659 TEA/ATTS transcription factor CaTec1p regulates hyphal development and
660 virulence in *Candida albicans*. *Mol Microbiol* 38:435-45.

- 661 33. Stoldt VR, Sonneborn A, Leuker CE, Ernst JF. 1997. Efg1p, an essential regulator
662 of morphogenesis of the human pathogen *Candida albicans*, is a member of a
663 conserved class of bHLH proteins regulating morphogenetic processes in fungi.
664 *Embo J* 16:1982-91.
- 665 34. Liu H, Kohler J, Fink GR. 1994. Suppression of hyphal formation in *Candida*
666 *albicans* by mutation of a *STE12* homolog. *Science* 266:1723-6.
- 667 35. Braun BR, Johnson AD. 1997. Control of filament formation in *Candida albicans*
668 by the transcriptional repressor TUP1. *Science* 277:105-9.
- 669 36. Min K, Biermann A, Hogan DA, Konopka JB. 2018. Genetic analysis of NDT80
670 family transcription factors in *Candida albicans* using new CRISPR-Cas9
671 approaches. *mSphere* 3: 00545-18.
- 672 37. Murad AM, Leng P, Straffon M, Wishart J, Macaskill S, MacCallum D, Schnell N,
673 Talibi D, Marechal D, Tekaia F, d'Enfert C, Gaillardin C, Odds FC, Brown AJ. 2001.
674 *NRG1* represses yeast-hypha morphogenesis and hypha-specific gene
675 expression in *Candida albicans*. *EMBO J* 20:4742-52.
- 676 38. Banerjee M, Thompson DS, Lazzell A, Carlisle PL, Pierce C, Monteagudo C,
677 Lopez-Ribot JL, Kadosh D. 2008. UME6, a novel filament-specific regulator of
678 *Candida albicans* hyphal extension and virulence. *Mol Biol Cell* 19:1354-65.
- 679 39. Lu Y, Su C, Wang A, Liu H. 2011. Hyphal development in *Candida albicans*
680 requires two temporally linked changes in promoter chromatin for initiation and
681 maintenance. *PLoS Biol* 9:e1001105.

- 682 40. Su C, Li Y, Lu Y, Chen J. 2009. Mss11, a transcriptional activator, is required for
683 hyphal development in *Candida albicans*. *Eukaryot Cell* 8:1780-91.
- 684 41. Pan X, Heitman J. 2002. Protein kinase A operates a molecular switch that governs
685 yeast pseudohyphal differentiation. *Mol Cell Biol* 22:3981-93.
- 686 42. Vylkova S, Carman AJ, Danhof HA, Collette JR, Zhou H, Lorenz MC. 2011. The
687 fungal pathogen *Candida albicans* autoinduces hyphal morphogenesis by raising
688 extracellular pH. *mBio* 2:e00055-11.
- 689 43. Donner AJ, Ebmeier CC, Taatjes DJ, Espinosa JM. 2010. CDK8 is a positive
690 regulator of transcriptional elongation within the serum response network. *Nat*
691 *Struct Mol Biol* 17:194-201.
- 692 44. Poss ZC, Ebmeier CC, Odell AT, Tangpeerachaikul A, Lee T, Pelish HE, Shair
693 MD, Dowell RD, Old WM, Taatjes DJ. 2016. Identification of Mediator Kinase
694 Substrates in Human Cells using Cortistatin A and Quantitative
695 Phosphoproteomics. *Cell Rep* 15:436-50.
- 696 45. Hnisz D, Majer O, Frohner IE, Komnenovic V, Kuchler K. 2010. The Set3/Hos2
697 histone deacetylase complex attenuates cAMP/PKA signaling to regulate
698 morphogenesis and virulence of *Candida albicans*. *PLoS Pathog* 6:e1000889.
- 699 46. Philip S, Kumarasiri M, Teo T, Yu M, Wang S. 2018. Cyclin-Dependent Kinase 8:
700 A New Hope in Targeted Cancer Therapy? *J Med Chem* 61:5073-5092.

- 701 47. Min K, Ichikawa Y, Woolford CA, Mitchell AP. 2016. *Candida albicans* gene
702 deletion with a transient CRISPR-Cas9 system. *mSphere* 1.
- 703 48. Grahl N, Demers EG, Crocker AW, Hogan DA. 2017. Use of RNA-Protein
704 complexes for genome editing in non-*albicans Candida* species. *mSphere* 2.
- 705 49. Guidi BW, Bjornsdottir G, Hopkins DC, Lacomis L, Erdjument-Bromage H, Tempst
706 P, Myers LC. 2004. Mutual targeting of mediator and the TFIID kinase Kin28. *J*
707 *Biol Chem* 279:29114-20.
- 708 50. Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, Kong L, Gao G, Li CY, Wei L. 2011.
709 KOBAS 2.0: a web server for annotation and identification of enriched pathways
710 and diseases. *Nucleic Acids Res* 39:W316-22.
- 711 51. Zhang A, Liu Z, Myers LC. 2013. Differential regulation of white-opaque switching
712 by individual subunits of *Candida albicans* mediator. *Eukaryot Cell* 12:1293-304.
- 713 52. Kettenbach AN, Gerber SA. 2011. Rapid and reproducible single-stage
714 phosphopeptide enrichment of complex peptide mixtures: application to general
715 and phosphotyrosine-specific phosphoproteomics experiments. *Anal Chem*
716 83:7635-44.
- 717 53. Grassetti AV, Hards R, Gerber SA. 2017. Offline pentafluorophenyl (PFP)-RP
718 prefractionation as an alternative to high-pH RP for comprehensive LC-MS/MS
719 proteomics and phosphoproteomics. *Anal Bioanal Chem* 409:4615-4625.

- 720 54. Ting L, Rad R, Gygi SP, Haas W. 2011. MS3 eliminates ratio distortion in isobaric
721 multiplexed quantitative proteomics. *Nat Methods* 8:937-40.
- 722 55. McAlister GC, Nusinow DP, Jedrychowski MP, Wuhr M, Huttlin EL, Erickson BK,
723 Rad R, Haas W, Gygi SP. 2014. MultiNotch MS3 enables accurate, sensitive, and
724 multiplexed detection of differential expression across cancer cell line proteomes.
725 *Anal Chem* 86:7150-8.
726

727 **Acknowledgments**

728 Research reported in this publication was supported by National Institute of Health
729 (NIH) through the National Institute of Allergy and Infectious Disease grants AI127548
730 to D.A.H., AI115253 to L.C. M., and T32 AI007519 to J.M.H. and National Institute for
731 General Medical Science grant R35 GM119455 for A.N.K.. This work was also
732 supported by P30-DK117469 for the Applied Bioinformatics and Biostatistics Core.
733 Sequencing services and specialized equipment was provided by the Genomics and
734 Molecular Biology Shared Resource Core at Dartmouth supported by NCI Cancer
735 Center Support Grant 5P30CA023108-37. Equipment used was supported by the NIH
736 IDeA award to Dartmouth BioMT P20-GM113132. The content is solely the
737 responsibility of the authors and does not necessarily represent the official views of the
738 NIH.
739

740 **Tables:**

741

742

	Down > 2-fold	Up > 2-fold	Total Down	Total Up
743 Total phosphopeptides	977	264	2967	2522
Total phosphoproteins	552	202	1165	1057
744 S/T#P motif phosphopeptides	293	94	943	867
S/T#P motif phosphoproteins	218	77	505	493

745

746 **Table 1.** Summary of phosphopeptides and phosphoproteins detected by motif.

747 Analysis limited to those peptides to which P-values of <0.05 were assigned in the

748 comparison of *ssn3^{AS}* to SC5134 wild type (WT). Down indicates phosphopeptides

749 lower in *ssn3^{AS}* treated with 3-MB-PP1 compared to WT treated with 3-MB-PP1; up

750 indicates phosphopeptides that were more abundant in the *ssn3^{AS}* strain treated with 3-

751 MB-PP1 compared to WT treated with 3-MB-PP1. The total refers to the number of

752 peptides or proteins that are significantly different regardless of fold-difference. “#”

753 indicates the detected phosphorylation on a serine or threonine, S/T, in either a -1

754 position relative to a proline, S/T#P motif.

755

756 **Figure Legends:**

757

758 **Figure 1.** 3-MB-PP1 inhibits the activity of analog-sensitive Ssn3^{AS}, but not Ssn3^{WT} *in*
759 *vitro*. *In vitro* kinase reactions contained purified Mediator from a strain with Ssn3^{WT} or
760 Ssn3^{AS}, ³²P-ATP, purified GST-tagged RNA Pol II C-terminal domain (CTD) and the
761 indicated concentrations of 3-MB-PP1 inhibitor. Reactions were analyzed by SDS-PAGE
762 and visualized by phosphorimaging.

763

764 **Figure 2.** 3-MB-PP1 stimulates hyphal growth in a strain bearing analog-sensitive alleles
765 of *SSN3*. **A.** Morphology of wild type (WT) SC5314, *ssn3*^{AS} and *ssn3*^{KD} strains was
766 assessed after growth in either 5 μM 3-MB-PP1 or vehicle (DMSO) for 3h at 30°C.
767 Quantification of yeast, pseudohyphae and hyphae in cultures by microscopic analysis of
768 blinded samples. ANOVA with multiple comparisons for the hyphal cell populations
769 shown. ****, p<0.001, ns, not significant; a, p<0.001 for comparison to WT with 3MB-PP1;
770 b, p<0.001 comparison to WT with DMSO. **B.** Representative images of cell populations
771 from cultures analyzed in panel A.

772

773 **Figure 3.** Heat map for genes induced upon inhibition of Ssn3^{AS} by 3-MB-PP1. Seventy-
774 seven genes were 2-fold higher in both the comparison of Ssn3^{AS} with 3-MB-PP1
775 compared to WT with 3-MB-PP1 and of Ssn3^{AS} with 3-MB-PP1 compared to with the
776 DMSO control. The heat map shows Log2-transformed counts per million for expressed
777 transcripts.

778

779 **Figure 4.** Overview of proteins for which two phosphopeptides were lower by >2 fold upon
780 inhibition of Ssn3. Focusing on peptides that were significantly lower in Ssn3^{AS} treated
781 with 3-MB-PP1 relative to control cultures (p<0.05 FDR-corrected), we found 977
782 peptides that were 2-fold lower upon 3-MB-PP1 inhibition of *ssn3^{AS}* relative to changes in
783 SC5314 WT. Two hundred and eighteen proteins had two more peptides that met these
784 criteria, forty of which were predicted to have nuclear localization. Med4 is a validated *C.*
785 *albicans* Ssn3 target. If an alias is available for an unnamed gene, it is shown in
786 parentheses.

787
788 **Figure 5.** *SSN3* repression of filamentation is *FLO8* dependent. A. Colony morphology
789 of a wild type *C. albicans* strain (SC5314), *ssn3Δ/Δ*, *flo8Δ/Δ* and *ssn3Δ/Δ flo8Δ/Δ* strains
790 grown on YNBA agar medium alone or supplemented with 110 mM glucose at 30°C or
791 on YNBA at 37°C. B. Cell morphology of strains tested in (A) after cells were grown in
792 YNBN_{2.5}AG₁₁ at 30°C for 3 hours. C. NanoString analysis of indicated hypha-specific
793 genes over-expression in the SC5314 wild type, and *ssn3Δ/Δ*, and *ssn3Δ/Δflo8Δ/Δ*
794 mutants. RNA was extracted from cells grown as indicated for (B) but for 75 minutes.
795 Gene expression was represented by mean and standard deviation after normalization to
796 Nanostring positive controls, and *TEF1* and *ACT1* reference transcripts; expression of
797 each gene in the wild type strain (SC5314) was set to '1'; **, p<0.01 and ***,p<0.001. D.
798 The embedded colonies of the same set of strains shown in (A) grown in YPS at 25°C.

799 **Figure 6.** Residues identified as phosphorylation sites influence Flo8 function. A.
800 SC5314 wild type, *ssn3Δ/Δ*, *flo8Δ/Δ* and *ssn3Δ/Δflo8Δ/Δ* strains were imaged after growth
801 as colonies on YNBA or YNBA+110 mM glucose at 37°C. *flo8Δ/Δ* and *ssn3Δ/Δflo8Δ/Δ*

802 expressing C-terminally 3XHA tagged Flo8^{WT}, Flo8^{T589A/S620A} or Flo8^{T589E/S620E} were also
803 included. B. Cell morphology of SC5314, *flo8Δ/Δ*, and *flo8Δ/Δ* expressing 3XHA-tagged
804 Flo8^{WT}, Flo8^{T589A,S620A} or Flo8^{T589E,S620E} after growth in YNBN_{2.5}AG₁₁ at 30°C for 3h. C.
805 Gene expression in *flo8Δ/Δ* expressing 3XHA-tagged Flo8^{WT} or Flo8^{T589A/S620A} relative to
806 *flo8Δ/Δ* after growth in YNBNAG for ~2h. Data show the mean and standard deviation
807 from measurement on triplicate RNA samples. Gene expression in *flo8* mutant (not
808 shown) was set to '1'. P-values (t-tests) were directly denoted or indicated by '**' (p<0.05),
809 '***'(p<0.01) or '****' (p<0.001) to show statistically significant differences. D.
810 Immunoblotting analysis with an α-HA antibody showing levels and gel mobility of native
811 Flo8 with the C-terminal 3X-HA tag or variants with T589A,S620A or T589E,S620E
812 substitutions; proteins were expressed in either *flo8Δ/Δ* or *ssn3Δ/Δ flo8Δ/Δ* backgrounds
813 and were grown in YNBAG at 30°C to mid-log phase. E. Flo8-HA levels in strains with full
814 Ssn3 activity, SC5314 (Ssn3^{WT}) and *ssn3^{AS}*, or without Ssn3 activity (*ssn3Δ/Δ* or *ssn3^{KD}*).
815

816 **Figure 7.** Medium alkalization is affected by Ssn3 and Stp2. A. Comparison of medium
817 pH by growth of SC5314, *ssn3Δ/Δ*, *stp2Δ/Δ* and *ssn3Δ/Δ stp2Δ/Δ* strains at 37°C. B. *ssn3*
818 hyperalkalinization phenotype is dependent on *FLO8* at 37°C. SC5314, *ssn3Δ/Δ*, *flo8Δ/Δ*
819 and *ssn3Δ/Δ flo8Δ/Δ* alone or expressing C-terminally 3XHA tagged Flo8^{WT},
820 Flo8^{T589A/S620A} or Flo8^{T589E/S620E}. Medium pH was assessed on YNBA with increasing
821 concentrations of glucose and bromocresol purple as a pH indicator.
822

823 **Figure S1.** *FLO8* is required for hyperfilamentation in an *efg1Δ/Δ* mutant in embedded
824 conditions and in colony biofilms. A. SC5314 wild type parental strain, *flo8Δ/Δ*, *flo8Δ/Δ*

825 complemented with *FLO8*, *efg1Δ/Δ*, *efg1Δ/Δflo8Δ/Δ*, *efg1Δ/Δflo8Δ/Δ+FLO8* as embedded
826 colonies in YPS agar 23°C or YNBA agar with 110 mM glucose at 30°C. The *efg1Δ/Δ* is
827 hyperfilamentous in embedded colony conditions and the filamentation is dependent on
828 *FLO8*.

829 **Supplementary Data:**

830

831 **Table S1.** Strains used in this work.

832

833 **Table S2.** RNA seq analyses to determine the effects of specific inhibition of *ssn3-as* by
834 3-MB-PP1 (drug). Sheets one and two compare the effect of drug versus vehicle in
835 SC5314 and *ssn3as*, respectively.

836

837 **Table S3.** Phosphoproteomic analysis of the effect of 3-MB-PP1 on *ssn3^{as}* versus
838 SC5314. Sheet one provides an annotated summary of phosphopeptides statistically
839 significantly altered by drug treatment of compared to drug treatment of SC5314.
840 Peptides highlighted in red indicate phosphorylation of a serine or threonine with a proline
841 in the +1 or +2 position. Sheet two provides the data with each replicate of the triplicate
842 experiment parsed individually.

843

844 **Table S4.** KEGG pathway enrichment analysis of transcripts altered in abundance in the
845 *ssn3^{as}* strain by 3-MB-PP1 treatment vs vehicle.

bioRxiv preprint doi: <https://doi.org/10.1101/2021.06.10.447844>; this version posted June 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.




Figure 1. 3-MB-PP1 inhibits the activity of analog-sensitive Ssn3^{AS}, but not Ssn3^{WT} *in vitro*. *In vitro* kinase reactions contained purified Mediator from a strain with Ssn3^{WT} or Ssn3^{AS}, ³²P-ATP, purified GST-tagged RNA Pol II C-terminal domain (CTD) and the indicated concentrations of 3-MB-PP1 inhibitor. Reactions were analyzed by SDS-PAGE and visualized by phosphorimaging.




Figure 2. 3-MB-PP1 stimulates hyphal growth in a strain bearing analog-sensitive alleles of *SSN3*. **A.** Morphology of wild type (WT) SC5314, *ssn3^{AS}* and *ssn3^{KD}* strains was assessed after growth in either 5 μ M 3-MB-PP1 or vehicle (DMSO) for 3h at 30°C. Quantification of yeast, pseudohyphae and hyphae in cultures by microscopic analysis of blinded samples. ANOVA with multiple comparisons for the hyphal cell populations shown. ****, $p < 0.001$, ns, not significant; a, $p < 0.001$ for comparison to WT with 3MB-PP1; b, $p < 0.001$ comparison to WT with DMSO. **B.** Representative images of cell populations from cultures analyzed in panel A.




Figure 3. Heat map for genes induced upon inhibition of Ssn3^{AS} by 3-MB-PP1. Seventy-seven genes were 2-fold higher in both the comparison of Ssn3^{AS} with 3-MB-PP1 compared to WT with 3-MB-PP1 and of Ssn3^{AS} with 3-MB-PP1 compared to with the DMSO control. The heat map shows Log2-transformed counts per million for expressed transcripts.

977 peptides with decreased phosphorylation >2 fold upon Ssn3^{AS} inhibition with 3-MB-PP1



218 proteins with 2 or more peptides with decreased phosphorylation >2 fold with Ssn3 inhibition




bioRxiv preprint doi: <https://doi.org/10.1101/2021.06.10.447844>; this version posted June 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

41 putative Ssn3 targets with known or predicted nuclear localization


Blm3, Bre1, Bur1, Cdc54, Cet1, Crz1, Cta8, Dbp3, Def1, Eaf7, Eed1, Fip1, Flo8, Isw2, Kel1, Krr1, Leu3, Med4, Mob2, Msn4, Not5, Pwp2, Rrp36, Rtg1, Rtg3, Set1, Set3, Smt3, Snf2, Stb3, Taf12, Zds1, C1_03360W(Chd1), C1_13880C(Zms1), C2_08720W, C2_09880C, C2_05640W(Bas1), C3_03670W(Hda2), C6_01590W, CR_02510W, CR_04110W(Naf1)

Figure 4. Overview of proteins for which two phosphopeptides were lower by >2 fold upon inhibition of Ssn3. Focusing on peptides that were significantly lower in Ssn3^{AS} treated with 3-MB-PP1 relative to control cultures (p<0.05 FDR-corrected), we found 977 peptides that were 2-fold lower upon 3-MB-PP1 inhibition of *ssn3^{AS}* relative to changes in SC5314 WT. Two hundred and eighteen proteins had two more peptides that met these criteria, forty of which were predicted to have nuclear localization. Med4 is a validated *C. albicans* Ssn3 target. If an alias is available for an unnamed gene, it is shown in parentheses.


A



B



C



D




Figure 5. *SSN3* repression of filamentation is *FLO8* dependent. A. Colony morphology of a wild type *C. albicans* strain (SC5314), *ssn3Δ/Δ*, *flo8Δ/Δ* and *ssn3Δ/Δ flo8Δ/Δ* strains grown on YNBA agar medium alone or supplemented with 110 mM glucose at 30°C or on YNBA at 37°C. B. Cell morphology of strains tested in (A) after cells were grown in YNBN_{2.5}AG₁₁ at 30°C for 3 hours. C. NanoString analysis of indicated hypha-specific genes over-expression in the SC5314 wild type, and *ssn3Δ/Δ*, and *ssn3Δ/Δ flo8Δ/Δ* mutants. RNA was extracted from cells grown as indicated for (B) but for 75 minutes. Gene expression was represented by mean and standard deviation after normalization to Nanostring positive controls, and *TEF1* and *ACT1* reference transcripts; expression of each gene in the wild type strain (SC5314) was set to '1'; **, p<0.01 and ***, p<0.001. D. The embedded colonies of the same set of strains shown in (A) grown in YPS at 25°C.




Figure 6. Residues identified as phosphorylation sites influence Flo8 function. A. SC5314 wild type, *ssn3Δ/Δ*, *flo8Δ/Δ* and *ssn3Δ/Δ flo8Δ/Δ* strains were imaged after growth as colonies on YNBA or YNBA+110 mM glucose at 37°C. *flo8Δ/Δ* and *ssn3Δ/Δ flo8Δ/Δ* expressing C-terminally 3XHA tagged *Flo8^{WT}*, *Flo8^{T589A/S620A}* or *Flo8^{T589E/S620E}* were also included. B. Cell morphology of SC5314, *flo8Δ/Δ*, and *flo8Δ/Δ* expressing 3XHA-tagged *Flo8^{WT}*, *Flo8^{T589A/S620A}* or *Flo8^{T589E/S620E}* after growth in YNBN_{2.5}AG₁₁ at 30°C for 3h. C. Gene expression in *flo8Δ/Δ* expressing 3XHA-tagged *Flo8^{WT}* or *Flo8^{T589A/S620A}* relative to *flo8Δ/Δ* after growth in YNBNAG for ~2h. Data show the mean and standard deviation from measurement on triplicate RNA samples. Gene expression in *flo8* mutant (not shown) was set to '1'. P-values (t-tests) were directly denoted or indicated by "*" (p<0.05), "***" (p<0.01) or "****" (p<0.001) to show statistically significant differences. D. Immunoblotting analysis with an α-HA antibody showing levels and gel mobility of native Flo8 with the C-terminal 3X-HA tag or variants with T589A,S620A or T589E,S620E substitutions; proteins were expressed in either *flo8Δ/Δ* or *ssn3Δ/Δ flo8Δ/Δ* backgrounds and were grown in YNBAG at 30°C to mid-log phase. E. Flo8-HA levels in strains with full Ssn3 activity, SC5314 (*Ssn3^{WT}*) and *ssn3^{AS}*, or without Ssn3 activity (*ssn3Δ/Δ* or *ssn3^{KD}*).




Figure 7. Medium alkalinization is affected by Ssn3 and Stp2. A. Comparison of medium pH by growth of SC5314, *ssn3Δ/Δ*, *stp2Δ/Δ* and *ssn3Δ/Δ stp2Δ/Δ* strains at 37°C. B. *ssn3* hyperalkalinization phenotype is dependent on *FLO8* at 37°C. SC5314, *ssn3Δ/Δ*, *flo8Δ/Δ* and *ssn3Δ/Δ flo8Δ/Δ* alone or expressing C-terminally 3XHA tagged *Flo8*^{WT}, *Flo8*^{T589A/S620A} or *Flo8*^{T589E/S620E}. Medium pH was assessed on YNBA with increasing concentrations of glucose and bromocresol purple as a pH indicator.